Search
FDA expands Sprycel approval to include certain children with acute lymphoblastic leukemia
- OPACC
- Jan 3, 2019
- 1 min read
The FDA expanded the approval of dasatinib tablets to include its use with chemotherapy for children aged 1 year or older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Recent Posts
See AllDuring cancer treatment, children can face hurdles to maintaining healthy eating. Chemotherapy has many side effects, including loss of...
Quality of life improvements can be made if clinicians better understand auditory attention decay after cancer treatment in pediatric...
A team of experts, issuing a statement on behalf of the American Heart Association, have detailed cardiometabolic considerations for...
Comments